Clayton CC, Bruchas MR, Lee ML, Chavkin C (2010) Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy. Mol Pharmacol 77, 339-47 19959593

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y166-p - MOR-1 (rat) ▲

Modsite: CTMSVDRyIAVCHPV SwissProt Entrez-Gene Orthologous residues MOR‑1 (human): Y168‑p, MOR‑1 iso5 (human): Y168‑p, MOR‑1 (mouse): Y166‑p, MOR‑1 (rat): Y166‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes DAMGO no change compared to control H2O2 no change compared to control H2O2, DAMGO increase EGF no change compared to control DAMGO, EGF increase naloxone DAMGO, EGF inhibit treatment-induced increase PP2 DAMGO, EGF inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  activity, inhibited Comments:  reduces G-protein coupling efficiency of the mu opioid receptor